PMID- 35898703
OWN - NLM
STAT- MEDLINE
DCOM- 20220729
LR  - 20220803
IS  - 2162-402X (Electronic)
IS  - 2162-4011 (Print)
IS  - 2162-4011 (Linking)
VI  - 11
IP  - 1
DP  - 2022
TI  - Peripheral gene signatures reveal distinct cancer patient immunotypes with 
      therapeutic implications for autologous DC-based vaccines.
PG  - 2101596
LID - 10.1080/2162402X.2022.2101596 [doi]
LID - 2101596
AB  - Dendritic cells (DCs) have received considerable attention as potential targets 
      for the development of novel cancer immunotherapies. However, the clinical 
      efficacy of DC-based vaccines remains suboptimal, largely reflecting local and 
      systemic immunosuppression at baseline. An autologous DC-based vaccine (DCVAC) 
      has recently been shown to improve progression-free survival and overall survival 
      in randomized clinical trials enrolling patients with lung cancer (SLU01, 
      NCT02470468) or ovarian carcinoma (SOV01, NCT02107937), but not metastatic 
      castration-resistant prostate cancer (SP005, NCT02111577), despite a good safety 
      profile across all cohorts. We performed biomolecular and cytofluorometric 
      analyses on peripheral blood samples collected prior to immunotherapy from 1000 
      patients enrolled in these trials, with the objective of identifying 
      immunological biomarkers that may improve the clinical management of 
      DCVAC-treated patients. Gene signatures reflecting adaptive immunity and T cell 
      activation were associated with favorable disease outcomes and responses to DCVAC 
      in patients with prostate and lung cancer, but not ovarian carcinoma. By 
      contrast, the clinical benefits of DCVAC were more pronounced among patients with 
      ovarian carcinoma exhibiting reduced expression of T cell-associated genes, 
      especially those linked to T(H2)-like signature and immunosuppressive regulatory 
      T (T(REG)) cells. Clinical responses to DCVAC were accompanied by signs of 
      antitumor immunity in the peripheral blood. Our findings suggest that circulating 
      signatures of antitumor immunity may provide a useful tool for monitoring the 
      potency of autologous DC-based immunotherapy.
CI  - (c) 2022 Sotio Biotech. Published with license by Taylor & Francis Group, LLC.
FAU - Hensler, Michal
AU  - Hensler M
AD  - Sotio Biotech, Prague, Czech Republic.
FAU - Rakova, Jana
AU  - Rakova J
AD  - Sotio Biotech, Prague, Czech Republic.
FAU - Kasikova, Lenka
AU  - Kasikova L
AD  - Sotio Biotech, Prague, Czech Republic.
FAU - Lanickova, Tereza
AU  - Lanickova T
AD  - Sotio Biotech, Prague, Czech Republic.
AD  - Department of Immunology, Charles University, 2nd Faculty of Medicine and 
      University Hospital Motol, Prague, Czech Republic.
FAU - Pasulka, Josef
AU  - Pasulka J
AD  - Sotio Biotech, Prague, Czech Republic.
FAU - Holicek, Peter
AU  - Holicek P
AD  - Sotio Biotech, Prague, Czech Republic.
AD  - Department of Immunology, Charles University, 2nd Faculty of Medicine and 
      University Hospital Motol, Prague, Czech Republic.
FAU - Hraska, Marek
AU  - Hraska M
AD  - Sotio Biotech, Prague, Czech Republic.
FAU - Hrnciarova, Tereza
AU  - Hrnciarova T
AD  - Sotio Biotech, Prague, Czech Republic.
FAU - Kadlecova, Pavla
AU  - Kadlecova P
AD  - Sotio Biotech, Prague, Czech Republic.
FAU - Schoenenberger, Andreu
AU  - Schoenenberger A
AD  - Sotio Biotech, Prague, Czech Republic.
FAU - Sochorova, Klara
AU  - Sochorova K
AD  - Sotio Biotech, Prague, Czech Republic.
FAU - Rozkova, Daniela
AU  - Rozkova D
AD  - Sotio Biotech, Prague, Czech Republic.
FAU - Sojka, Ludek
AU  - Sojka L
AD  - Sotio Biotech, Prague, Czech Republic.
AD  - Department of Immunology, Charles University, 2nd Faculty of Medicine and 
      University Hospital Motol, Prague, Czech Republic.
FAU - Drozenova, Jana
AU  - Drozenova J
AD  - Department of Pathology 3rd Faculty of Medicine, And University Hospital 
      Kralovske Vinohrady, Prague, Czech Republic.
FAU - Laco, Jan
AU  - Laco J
AD  - The Fingerland Department of Pathology, Charles University, Faculty of Medicine 
      and University Hospital Hradec Kralove, Czech Republic.
FAU - Horvath, Rudolf
AU  - Horvath R
AD  - Department of Pediatric and Adult Rheumatology, University Hospital Motol, 
      Prague, Czech Republic.
FAU - Podrazil, Michal
AU  - Podrazil M
AD  - Sotio Biotech, Prague, Czech Republic.
AD  - Department of Immunology, Charles University, 2nd Faculty of Medicine and 
      University Hospital Motol, Prague, Czech Republic.
FAU - Hongyan, Guo
AU  - Hongyan G
AD  - Department of Gynecology and Obstetrics, Peking University Third Hospital, 
      Beijing, Hebei Province, China.
FAU - Brtnicky, Tomas
AU  - Brtnicky T
AD  - Department of Gynecology and Obstetrics, 1st Faculty of Medicine, Charles 
      University, University Hospital Bulovka, Prague, Czech Republic.
FAU - Halaska, Michal J
AU  - Halaska MJ
AD  - Department of Gynecology and Obstetrics, Charles University, 3rd Faculty of 
      Medicine and University Hospital Kralovske Vinohrady, Prague, Czech Republic.
FAU - Rob, Lukas
AU  - Rob L
AD  - Department of Gynecology and Obstetrics, Charles University, 3rd Faculty of 
      Medicine and University Hospital Kralovske Vinohrady, Prague, Czech Republic.
FAU - Ryska, Ales
AU  - Ryska A
AD  - The Fingerland Department of Pathology, Charles University, Faculty of Medicine 
      and University Hospital Hradec Kralove, Czech Republic.
FAU - Coosemans, An
AU  - Coosemans A
AD  - Department of Oncology, Leuven Cancer Institute, Laboratory of Tumor Immunology 
      and Immunotherapy, KU Leuven, Belgium.
FAU - Vergote, Ignace
AU  - Vergote I
AD  - Department of Oncology, Leuven Cancer Institute, Laboratory of Tumor Immunology 
      and Immunotherapy, KU Leuven, Belgium.
AD  - Department of Oncology, Leuven Cancer Institute, Laboratory of Gynaecologic 
      Oncology, KU Leuven, Belgium.
AD  - Department of Gynaecology and Obstetrics, Leuven Cancer Institute, UZ Leuven, 
      Leuven, Belgium.
FAU - Garg, Abhishek D
AU  - Garg AD
AD  - Laboratory of Cell Stress and Immunity, Department of Cellular and Molecular 
      Medicine, KU Leuven, Leuven, Belgium.
FAU - Cibula, David
AU  - Cibula D
AD  - Gynecologic Oncology Center, Department of Obstetrics and Gynecology, 1st Faculty 
      of Medicine, Charles University and General University Hospital, Prague, Czech 
      Republic.
FAU - Bartunkova, Jirina
AU  - Bartunkova J
AD  - Sotio Biotech, Prague, Czech Republic.
AD  - Department of Immunology, Charles University, 2nd Faculty of Medicine and 
      University Hospital Motol, Prague, Czech Republic.
FAU - Spisek, Radek
AU  - Spisek R
AD  - Sotio Biotech, Prague, Czech Republic.
AD  - Department of Immunology, Charles University, 2nd Faculty of Medicine and 
      University Hospital Motol, Prague, Czech Republic.
FAU - Fucikova, Jitka
AU  - Fucikova J
AD  - Sotio Biotech, Prague, Czech Republic.
AD  - Department of Immunology, Charles University, 2nd Faculty of Medicine and 
      University Hospital Motol, Prague, Czech Republic.
LA  - eng
SI  - ClinicalTrials.gov/NCT02470468
SI  - ClinicalTrials.gov/NCT02107937
SI  - ClinicalTrials.gov/NCT02111577
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220722
PL  - United States
TA  - Oncoimmunology
JT  - Oncoimmunology
JID - 101570526
RN  - 0 (Cancer Vaccines)
SB  - IM
MH  - *Cancer Vaccines/therapeutic use
MH  - Carcinoma, Ovarian Epithelial/drug therapy
MH  - Dendritic Cells/metabolism
MH  - Female
MH  - Humans
MH  - *Lung Neoplasms/drug therapy/therapy
MH  - Male
MH  - *Ovarian Neoplasms/genetics/therapy
PMC - PMC9311316
OTO - NOTNLM
OT  - Cancer immunotherapy
OT  - anti-PD-1
OT  - circulating biomarkers
OT  - epithelial ovarian carcinoma
OT  - metastatic castrate-resistant prostate cancer
OT  - non-small cell lung carcinoma
COIS- IV declares consulting for AstraZeneca, Clovis Oncology Inc., Carrick 
      Therapeutics, Deciphera Pharmaceuticals, Elevar Therapeutics, F. Hoffmann-La 
      Roche Ltd, Genmab, GSK, Immunogen Inc., Jazzpharma, Mersana, Millennium 
      Pharmaceuticals, MSD, Novocure, Octimet Oncology NV, Oncoinvent AS, Sotio a.s., 
      Verastem Oncology, Zentalis; contracted research for: Oncoinvent AS, Genmab; and 
      research funding from Amgen and Roche. RS and JB are minority shareholders of 
      Sotio. ADG received fees for consultancy, lectures or services from Boehringer 
      Ingelheim (Germany), Miltenyi Biotec (Germany), Isoplexis (USA) and Novigenix 
      (Switzerland). AR declares advisory services and invited lectures for Amgen, 
      AstraZeneca, BMS, Eli-Lilly, Janssen-Cilag, MSD, and Roche. AC is a contracted 
      researcher for Oncoinvent AS and Novocure and a consultant for Sotio Biotech a.s. 
      MH, JR, LK, TL, JF, PH, MH, TH, PK, KS, DR, LS, JB, RS, and JF are employees of 
      Sotio a.s. The other authors declare no conflicts of interest.
EDAT- 2022/07/29 06:00
MHDA- 2022/07/30 06:00
PMCR- 2022/07/22
CRDT- 2022/07/28 02:14
PHST- 2022/07/28 02:14 [entrez]
PHST- 2022/07/29 06:00 [pubmed]
PHST- 2022/07/30 06:00 [medline]
PHST- 2022/07/22 00:00 [pmc-release]
AID - 2101596 [pii]
AID - 10.1080/2162402X.2022.2101596 [doi]
PST - epublish
SO  - Oncoimmunology. 2022 Jul 22;11(1):2101596. doi: 10.1080/2162402X.2022.2101596. 
      eCollection 2022.